Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01348828 · ClinicalTrials.gov registry record · NA
Feasibility and Safety Study of the Endologix Fenestrated Stent Graft System
A NA study, sponsored by Endologix.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT01348828: Completed NA study, sponsored by Endologix.
NCT01348828 is a NA study that has completed, run by Endologix. The registered enrollment target is 49 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01348828, a NA study, has completed, sponsored by Endologix.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate the safety and feasibility of the Endologix Fenestrated Stent Graft System for the endovascular repair of juxtarenal or pararenal aortic aneurysms.
Primary Outcome
Major adverse events defined as: * All-cause death * Bowel ischemia * Myocardial infarction * Paraplegia * Renal failure * Respiratory failure * Stroke * Blood loss \>=1,000cc
Interventions
- DEVICE Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2011-10-19 |
| Est. Completion | 2018-03-20 |
| Phase | NA |
What the finished NCT01348828 record still lists
NCT01348828 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System) is the first listed.
NCT01348828 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01348828 about?
NCT01348828 is a clinical study titled "Feasibility and Safety Study of the Endologix Fenestrated Stent Graft System". The aim of this study is to evaluate the safety and feasibility of the Endologix Fenestrated Stent Graft System for the endovascular repair of juxtarenal or pararenal aortic aneurysms.
What is the current status of trial NCT01348828?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2011-10-19. Estimated completion is 2018-03-20.
What interventions are being tested in trial NCT01348828?
The interventions under investigation include: Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System) (DEVICE).
Who is sponsoring clinical trial NCT01348828?
This trial is sponsored by Endologix, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01348828's enrollment target sits among peer trials
49 1379th of 2000 higher than 620 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI